Top Markets
Coin of the day
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

688336
Rangering i aksjer #3341
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Aksjekurs
$6.27
Markedsverdi
$5.62B
Endring (1 dag)
-0.46%
Endring (1 år)
26.35%
Land
CN
Handel Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)

Kategori

Inntekter for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Inntekter i 2026 TTM: 0
Ifølge Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH